Anavex Life Sciences Corp (AVXL)

[nidan7500]

A couple of observations from "tradeherpete's" work ref here:

Obviously these patients on Open Label Extension (OLE) will generate a lot of useful observational information. BUT, the lack of tools in use for clinical information generation (data generators) is very surprising. These are mostly human observations. There must be a better way. We need AI/other tools to measure/record CNS performance, real time-full time.

One patient that stands out that I just recently saw, was able to swallow her food better. She didn’t have any problems choking now that she’s on the active medication.

She was able then to eat better, happier. She had less bloating, less constipation and having better function GI wise I think can lead to less agitation.

The families were able to mark on the main outcome measures that were improved. The Rett Syndrome Behavior Questionaire that the parents answered and also the Clinical Global Improvements Scale. The CGII that the Clinicians do. There were significant improvements with the Anavex2-73.

So this is very exciting.. So far the patients want to continue on the Open Label Extension on this medication.

This is a relatively unique medication that can actually improve the calcium disregulation, the mitochondrial function, the oxidative stress and the neural connections. These problems can be seen in variety of other neural developmental disorders and also neurodegenerative disorders.